• $5.99

Publisher Description

ENPNewswire-November 7, 2011--J&J -FDA Approves XARELTO (Rivaroxaban) To Reduce The Risk Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation; XARELTO Combines Proven Effectiveness And Demonstrated Safety Profile With Convenient, Once-Daily Dosing(C)2011 ENPublishing - http://www.enpublishing.co.uk ENP Newswire - 07 November 2011

GENRE
Business & Personal Finance
RELEASED
2011
November 7
LANGUAGE
EN
English
LENGTH
8
Pages
PUBLISHER
Normans Media Ltd.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
92.1
KB

More Books by ENP Newswire